Planned System Maintenance

Starting Friday, December 21st, 2018 beginning at 5:00 PM EST, and ending on Friday, December 21st, 2018 at 11:00 PM EST. During this time there will be no access to the system including patient enrollments.
Please share this notification to the personnel who will be affected by this within your organization.
Maintenance Start: Friday, December 21st, 2018, 5:00 PM EST.
Maintenance End: Friday, December 21st, 2018, 11:00 PM EST.
We are sorry for any inconvenience this may cause.

Published: November 30, 2018

Dr. Kim Chi, Medical Oncologist, and Medical Director at BC Cancer leading the trial with Dr. Alexander Wyatt who is leading the DNA analysis and is a Senior Research Scientist at the Vancouver Prostate Centre and the Vancouver Coastal Health Research Institute.

A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients.

Published: September 24, 2018

The results of the CCTG LY.16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.

Published: October 09, 2018
Participation is open to women with confirmed genetic mutation BRCA1/BRCA2 but have not developed cancer

Participation is open to women with confirmed genetic mutation BRCA1 or BRCA2 but have not developed cancer

Taking aspirin is not a cancer treatment, but research suggests that the anti-inflammatory properties of acetylsalicylic acid (ASA) may reduce the chance of getting some cancers.

The Canadian Cancer Trials Group (CCTG) has recently opened the OV.25 clinical trial that investigates if taking ASA can help women prevent ovarian cancer. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer and researchers want to understand if an anti-inflammatory intervention can help reduce the risk.

Published: August 27, 2018
disease site IND and standing committees

Disease site committees

Disease site committees discuss proposals for new studies, consider their scientific merit and feasibility, and assign priorities when necessary. Currently, there are 10 disease site committees including brain, breast, lung, gastrointestinal, genitourinary, gynecologic, hematologic, melanoma, sarcoma, and symptom control.

Published: August 23, 2018
New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (
Published: August 14, 2018

Dr. Scott Bratman, researcher at Princess Margaret Cancer Centre and CCTG Senior Investigator Wendy Parulekar awarded CIHR grant for HN.10 study

The Canadian Institute of Health Research (CIHR) has announced a project grant award of $860,628 over six years for a research project lead by the Canadian Cancer Trials Group (CCTG). The HN.10 study will investigate the potential benefits of the de-escalation of treatment for patients with tonsil cancer.

Published: June 19, 2018
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

Published: June 14, 2018

The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.

Published: June 04, 2018

Dr. Jim Biagi, Queen's University Researcher & Oncologist at the Cancer Centre of South Eastern Ontario and the CCTG Canadian study co-chair with clinical trial participant Kathleen Kennedy

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.

Published: May 23, 2018

The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D).